6-Hydroxy-2-(methylsulfanyl)-4-pyrimidinecarboxylic Acid has shown binding to HCR-13pf of MMP-13 hemopexin domain with no crossreactivity to MMP-1 and 8 which could serve as building block for development of drug for osteoarthritis (OA) and rheumatoid arthritis (RA). It can be useful in the structure-??activity relationship studies of pyrimidine base analogs as ligands of orotate phosphoribosyltransferase as well as allosteric inhibitors of a mammalian lectin.
